Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study

Open access
Tassorelli, Cristina, Grazzi, Licia, de Tommaso, Marina, Pierangeli, Giulia, Martelletti, Paolo, Rainero, Innocenzo, Dorlas, Stefanie, Geppetti, Pierangelo, Ambrosini, Anna, Sarchielli, Paola, Liebler, Eric, Barbanti, Piero, On behalf of the PRESTO Study Group, PRESTO Study Group, Tassorelli, Cristina, Bitetto, Vito, De Icco, Roberto, Martinelli, Daniele, Sances, Grazia, Bianchi, Monica, Grazzi, Licia, Padovan, Anna Maria, de Tommaso, Marina, Ricci, Katia, Vecchio, Eleonora, Cortelli, Pietro, Cevoli, Sabina, Pierangeli, Giulia, Terlizzi, Rossana, Martelletti, Paolo, Negro, Andrea, Chiariello, Gabriella Addolorata, Rainero, Innocenzo, De Martino, Paola, Gai, Annalisa, Govone, Flora, Masuzzo, Federica, Rubino, Elisa, Torrieri, Maria Claudia, Vacca, Alessandro, Geppetti, Pierangelo, Chiarugi, Alberto, De Cesaris, Francesco, Puma, Simone Li, Lupi, Chiara, Marone, Ilaria, Ambrosini, Anna, Perrotta, Armando, Sarchielli, Paola, Bernetti, Laura, Corbelli, Ilenia, Romoli, Michele, Simoni, Simone, Verzina, Angela, Barbanti, Piero, Aurilia, Cinzia, Egeo, Gabriella, Fofi, Luisa, Liebler, Eric, Andersson, Annelie, Spitzer, Lia, Marin, Juana, McClure, Candace, Thackerey, Lisa, Baldi, Maria Giovanna, Di Maro, Daniela · 2018 · Neurology

Abstract

Objective To evaluate the efficacy, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS; gammaCore; electroCore, LLC, Basking Ridge, NJ) for the acute treatment of migraine in a multicenter, double-blind, randomized, sham-controlled trial. Methods A total of 248 participants with episodic migraine with/without aura were randomized to receive nVNS or sham within 20 minutes from pain onset. Participants were to repeat treatment if pain had not improved in 15 minutes. Results nVNS (n = 120) was superior to sham (n = 123) for pain freedom at 30 minutes (12.7% vs 4.2%; p = 0.012) and 60 minutes (21.0% vs 10.0%; p = 0.023) but not at 120 minutes (30.4% vs 19.7%; p = 0.067; primary endpoint; logistic regression) after the first treated attack. A post hoc repeated-measures test provided further insight into the therapeutic benefit of nVNS through 30, 60, and 120 minutes (odds ratio 2.3; 95% confidence interval 1.2, 4.4; p = 0.012). nVNS demonstrated benefits across other endpoints including pain relief at 120 minutes and was safe and well-tolerated. Conclusion This randomized sham-controlled trial supports the abortive efficacy of nVNS as early as 30 minutes and up to 60 minutes after an attack. Findings also suggest effective pain relief, tolerability, and practicality of nVNS for the acute treatment of episodic migraine. ClinicalTrials.gov identifier NCT02686034. Classification of evidence This study provides Class I evidence that for patients with an episodic migraine, nVNS significantly increases the probability of having mild pain or being pain-free 2 hours poststimulation (absolute difference 13.2%).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000005857

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Participant disposition AE = adverse event; ITT = intent-to-treat; nVNS = noninvasive vagus nerve stimulation. *Other reasons for discontinuation included inability to fulfill visits because of injury, inability to continue the study because of family commitments, dissatisfaction with or discontinued/lack of use of the device, and noncompliance with study procedures.
Figure 1 Participant disposition AE = adverse event; ITT = intent-to-treat; nVNS = noninvasive vagus nerve stimulation. *Other reasons for discontinuation included inability to fulfill visits because of injury, inability to continue the study because of family commitments, dissatisfaction with or discontinued/lack of use of the device, and noncompliance with study procedures.CC BY-NC-ND · PubMed Central
Figure 2 Responder rates after the first treated attack during the double-blind period (A) Pain freedom and (B) pain relief. CI = confidence interval; nVNS = noninvasive vagus nerve stimulation. Data for no. of participants in (A) are unadjusted numbers. *Statistically significant. **Primary endpoint.
Figure 2 Responder rates after the first treated attack during the double-blind period (A) Pain freedom and (B) pain relief. CI = confidence interval; nVNS = noninvasive vagus nerve stimulation. Data for no. of participants in (A) are unadjusted numbers. *Statistically significant. **Primary endpoint.CC BY-NC-ND · PubMed Central
Figure 3 Mean percentage pain score reductions Changes are from baseline for the first treated attack in the double-blind period; post hoc analysis. CI = confidence interval; nVNS = noninvasive vagus nerve stimulation. *Statistically significant.
Figure 3 Mean percentage pain score reductions Changes are from baseline for the first treated attack in the double-blind period; post hoc analysis. CI = confidence interval; nVNS = noninvasive vagus nerve stimulation. *Statistically significant.CC BY-NC-ND · PubMed Central
Figure 4 ≥50% responder rates at 120 minutes during the double-blind period CI = confidence interval; nVNS = noninvasive vagus nerve stimulation. *Statistically significant. **Post hoc analysis.
Figure 4 ≥50% responder rates at 120 minutes during the double-blind period CI = confidence interval; nVNS = noninvasive vagus nerve stimulation. *Statistically significant. **Post hoc analysis.CC BY-NC-ND · PubMed Central
Figure 5 Blinding nVNS = noninvasive vagus nerve stimulation. *Inclusion of zero in the 95% confidence interval (CI) indicates successful blinding.
Figure 5 Blinding nVNS = noninvasive vagus nerve stimulation. *Inclusion of zero in the 95% confidence interval (CI) indicates successful blinding.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 254

Metadata

Authors
Tassorelli, C., Grazzi, L., de Tommaso, M., Pierangeli, G., Martelletti, P., Rainero, I., Dorlas, S., Geppetti, P., Ambrosini, A., Sarchielli, P., Liebler, E., Barbanti, P., On behalf of the PRESTO Study Group, PRESTO Study Group, Tassorelli, C., Bitetto, V., De Icco, R., Martinelli, D., Sances, G., Bianchi, M., Grazzi, L., Padovan, A. M., de Tommaso, M., Ricci, K., Vecchio, E., Cortelli, P., Cevoli, S., Pierangeli, G., Terlizzi, R., Martelletti, P., Negro, A., Chiariello, G. A., Rainero, I., De Martino, P., Gai, A., Govone, F., Masuzzo, F., Rubino, E., Torrieri, M. C., Vacca, A., Geppetti, P., Chiarugi, A., De Cesaris, F., Puma, S. L., Lupi, C., Marone, I., Ambrosini, A., Perrotta, A., Sarchielli, P., Bernetti, L., Corbelli, I., Romoli, M., Simoni, S., Verzina, A., Barbanti, P., Aurilia, C., Egeo, G., Fofi, L., Liebler, E., Andersson, A., Spitzer, L., Marin, J., McClure, C., Thackerey, L., Baldi, M. G., & Di Maro, D.
Affiliations
University of Pavia (IT)
Venue
Neurology
Published
2018-07-24
Volume
91
Issue
4
Pages
e364-e373
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2808133247
Cited by
254
References
36
Citations by year
2026: 20 · 2025: 24 · 2024: 27 · 2023: 28 · 2022: 27 · 2021: 36 · 2020: 39 · 2019: 39 · 2018: 12
FWCI
24.62
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Neurology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
  • Florence Research (University of Florence) (submittedVersion, other-oa)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by-nc-nd)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by-nc-nd)
Funders
  • Abbott Laboratories
  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • Novartis
  • Sanofi
  • Teva Pharmaceutical Industries
  • Chiesi Farmaceutici
  • Mylan
  • TauRx Pharmaceuticals
  • European Commission (HORIZON2020)
  • Ministero della Salute
  • Almirall
  • Allergan
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
  • Life Sciences › Neuroscience › Neurology › Vagus Nerve Stimulation Research
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
Keywords
non-invasive vagus nerve stimulation, migraine, acute migraine treatment, abortive treatment, episodic migraine, migraine with aura, analgesia, tolerability, safety
MeSH terms
Adult, Double-Blind Method, Female, Humans, Male, Middle Aged, Migraine Disorders, Pain Measurement, Prospective Studies, Treatment Outcome, Vagus Nerve Stimulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. https://app.cochat.ai/papers/10.1212/wnl.0000000000005857
The paper
Tassorelli, C., Grazzi, L., de Tommaso, M., Pierangeli, G., Martelletti, P., Rainero, I., Dorlas, S., Geppetti, P., Ambrosini, A., Sarchielli, P., Liebler, E., Barbanti, P., On behalf of the PRESTO Study Group, PRESTO Study Group, Tassorelli, C., Bitetto, V., De Icco, R., Martinelli, D., Sances, G., . . . Di Maro, D. (2018). Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. Neurology. https://doi.org/10.1212/wnl.0000000000005857

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.